Spleen News and Research

RSS

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study.

19 May 2011

Bioengineering students redesign pediatric mannequin

Rice University bioengineering students have modified a child-size training mannequin to give medical students hands-on pediatric experience so that real patients can be spared further stress and pain.

17 May 2011

Researchers find temperature-sensing protein in immune cells

Researchers at The Scripps Research Institute have found a temperature-sensing protein within immune cells that, when tripped, allows calcium to pour in and activate an immune response.

7 May 2011

Exacerbate-reverse' approach can identify potential therapy for fatal childhood disease

Many genes that cause human diseases have parallel genes in other organisms, including yeast. Now Columbia University researchers have used an innovative yeast-based screening method to identify a possible treatment for the fatal childhood disease Niemann-Pick C.

19 Apr 2011

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

The U.S. Food and Drug Administration today approved Actemra, given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis in children ages 2 years and older.

15 Apr 2011

South Sudan health workers face worst Kala-azar outbreak

South Sudan is facing the worst outbreak of Kala-azar in the past 10 years as health workers from Servant's Heart Relief race against the clock to stop the spread of the deadly disease.

5 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011

Study provides insight into why older adults are so vulnerable to pneumonia

A study featured on the cover of the March 15 Journal of Immunology is providing insight into why the elderly are so vulnerable to pneumonia and other bacterial infections.

15 Mar 2011

Study provides insight into aging immune system

A study featured on the cover of the March 15 Journal of Immunology is providing insight into why the elderly are so vulnerable to pneumonia and other bacterial infections.

14 Mar 2011

Salmonella may serve as valuable tool to fight against cancer

University of Minnesota researchers are using salmonella - the bacteria commonly transmitted through food that sickens thousands of U.S. residents each year - to do what was once unthinkable: help people.

10 Mar 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

Viral infection of Leishmania leads to increased pathogenicity

A parasite and a virus may be teaming up in a way that increases the parasite's ability to harm humans, scientists at the University of Lausanne in Switzerland and Washington University School of Medicine in St. Louis report this week in Science.

11 Feb 2011

Dream Foundation to fulfill final dream for Stage III Pancreatic Cancer patient

On February 6, Dream Foundation, the first national wish-granting organization for adults in the end stages of life, will fulfill Ed Demyan's final dream - to witness the ultimate American sporting event, the Super Bowl. Demyan, 47, of Brooklyn, Ohio, is a proud father three daughters (11, 14, 22) and a future step-daughter (15).

5 Feb 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

Researchers find food-borne bacteria can cause difficult-to-treat heart infections

Researchers at the University of Illinois at Chicago College of Medicine have found that particular strains of a food-borne bacteria are able to invade the heart, leading to serious and difficult-to-treat heart infections.

27 Jan 2011

Scientists create particles that resemble RBC, pave way for development of synthetic blood

A team of scientists has created particles that closely mirror some of the key properties of red blood cells, potentially helping pave the way for the development of synthetic blood.

11 Jan 2011

Insecticidal nets do not always work against diseases transmitted by insect bites

Longlasting insecticidal nets yielded an important breakthrough in malaria prevention, but this does not automatically mean they always work against diseases transmitted by insect bites. Against the transmission of kala azar disease in India and Nepal they did not have an effect. This was reported by an international group of researchers, led by Marleen Boelaert of the Institute of Tropical Medicine Antwerp, in the reputed British Medical Journal.

5 Jan 2011